Migrende serum PROBDNF, BDNF ve plazminojen düzeylerinin incelenmesi
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Migren, nüfusun yaklaşık %12'sini etkileyen, ciddi bir hastalık yükü oluşturan ve etyolojisi henüz tam olarak anlaşılamamış bir baş ağrısı çeşididir. Nedenleri arasında genetik yatkınlığı ve patofizyolojik mekanizmaları içeren bazı teoriler bulunmaktadır. BDNF'de migren patofizyolojisinde CGRP ile ilişkisi sebebiyle önemli olabileceği düşünülen bir moleküldür. BDNF trigeminal ganglion nöronlarında CGRP ile ilişkilidir. BDNF ve CGRP'nin bu ilişkisinin, hastaların migrene duyarlılığını modüle etmede önemli bir rol oynayabileceğini öne sürülmüştür. Bu çalışmanın amacı migren tanısı almış hastalar ile migren tanısı almamış bireylerde serum BDNF, ProBDNF ve plazma plazminojen düzeyleri arasında bir farklılık olup olmadığını incelemektir. Düzce Üniversitesi Uygulama ve Araştırma Hastanesi Nöroloji Polikliniğinde migren tanısı almış 43 hasta migrenli grubu, migren tanısı olmayan ve hastanenin diğer polikliniklerine başvurmuş 43 kişi de kontrol grubunu oluşturdu. Veri toplama aracı olarak araştırmacıların düzenlemiş olduğu Hasta Bilgi Formu kullanıldı ve çalışmaya katılan kişilerden kan örnekleri alınarak BDNF, ProBDNF ve Plazminojen seviyeleri ölçüldü. Sayısal değişkenler için tanımlayıcı istatistikler aritmetik ortalama±standart sapma ve ortanca (minimum-maksimum), kategorik yapıdaki veriler için sayı ve yüzde olarak verildi. Migren grubu ve kontrol grubunun karşılaştırmalı analizlerinde kategorik veriler kikare testi ile, ölçüm değerleri parametrik ve nonparametrik verilerde uygun testler ile analiz edildi. İstatistiklerde p anlamlılık düzeyi p?0.05 olarak kabul edildi. Migren grubunda BDNF (112,23 ±12,49 pg/ml) ve ProBDNF (114,80±21,99 pg/ml) serum düzeyleri ortalamaları kontrol grubu BDNF ortalaması (168,04 ±59,48 pg/ml) ve ProBDNF (226,14 ±94,46 pg/ml) göre düşük bulunmuştur (p<0,001, p<0,001). Gruplar arasında plazma plazminojen düzeyi bakımından fark bulunmamıştır (p=0,577). Gruplar arasında BDNF ortalamalarının farklı olmasının, düşük dozlardaki BDNF'nin hiperaljezik etkisinden kaynaklandığı düşünülebilir. Anahtar Sözcükler: BDNF, Migren, Plazminojen, ProBDNF.
Migraine is a type of headache affects approximately 12% of the population, creates a serious burden of disease, and its etiology is not yet fully understood. There are some theories including genetic predisposition and pathophysiological mechanisms among its causes. BDNF is a molecule that is thought to be important in migraine pathophysiology due to its relationship with CGRP. BDNF is associated with CGRP in trigeminal ganglion neurons. It has been suggested that this association of BDNF and CGRP may play an important role in modulating patients' susceptibility to migraine. The aim of this research was to examine whether there is a difference between serum BDNF, proBDNF, and plasma plasminogen levels in patients diagnosed with migraine and individuals not diagnosed with migraine. Forty-three patients diagnosed with migraine in Düzce University Practice and Research Hospital Neurology Outpatient Clinic constituted the migraine group, and 43 patients without a diagnosis of migraine who applied to other polyclinics of the hospital constituted the control group. The Patient Information Form prepared by the researchers was used as a data collection tool, and blood samples were taken from the people participating in the research, and the levels of BDNF, ProBDNF and Plasminogen were measured. Descriptive statistics for scale variables were given as mean±standard deviation and median (minimum-maximum), categorical variables were given as numbers and percentages. In the comparative analysis of migraine group and control group, categorical data were analyzed with chi-square test, and measurement values were analyzed with appropriate tests in parametric and nonparametric data. The statistical significance level of p was accepted as p?0.05. Mean serum levels of BDNF (112.23 ±12.49 pg/ml) and ProBDNF (114.80±21.99 pg/ml) in the migraine group, mean BDNF in the control group (168.04 ±59.48 pg/ml) and ProBDNF (p<0.001, p<0.001). There was no difference between the groups in terms of plasma plasminogen level (p=0.577). It may be thought that the difference in BDNF averages between the groups may be due to the hyperalgesic effect of low doses of BDNF. Keywords: BDNF, Migraine, Plasminogen, proBDNF.
Migraine is a type of headache affects approximately 12% of the population, creates a serious burden of disease, and its etiology is not yet fully understood. There are some theories including genetic predisposition and pathophysiological mechanisms among its causes. BDNF is a molecule that is thought to be important in migraine pathophysiology due to its relationship with CGRP. BDNF is associated with CGRP in trigeminal ganglion neurons. It has been suggested that this association of BDNF and CGRP may play an important role in modulating patients' susceptibility to migraine. The aim of this research was to examine whether there is a difference between serum BDNF, proBDNF, and plasma plasminogen levels in patients diagnosed with migraine and individuals not diagnosed with migraine. Forty-three patients diagnosed with migraine in Düzce University Practice and Research Hospital Neurology Outpatient Clinic constituted the migraine group, and 43 patients without a diagnosis of migraine who applied to other polyclinics of the hospital constituted the control group. The Patient Information Form prepared by the researchers was used as a data collection tool, and blood samples were taken from the people participating in the research, and the levels of BDNF, ProBDNF and Plasminogen were measured. Descriptive statistics for scale variables were given as mean±standard deviation and median (minimum-maximum), categorical variables were given as numbers and percentages. In the comparative analysis of migraine group and control group, categorical data were analyzed with chi-square test, and measurement values were analyzed with appropriate tests in parametric and nonparametric data. The statistical significance level of p was accepted as p?0.05. Mean serum levels of BDNF (112.23 ±12.49 pg/ml) and ProBDNF (114.80±21.99 pg/ml) in the migraine group, mean BDNF in the control group (168.04 ±59.48 pg/ml) and ProBDNF (p<0.001, p<0.001). There was no difference between the groups in terms of plasma plasminogen level (p=0.577). It may be thought that the difference in BDNF averages between the groups may be due to the hyperalgesic effect of low doses of BDNF. Keywords: BDNF, Migraine, Plasminogen, proBDNF.
Açıklama
Anahtar Kelimeler
Fizyoloji, Physiology
